Celsion Corporation (NASDAQ:CLSN) Set to Announce Quarterly Earnings on Thursday
Celsion Corporation (NASDAQ:CLSN) will issue its quarterly earnings data before the market opens on Thursday, August 10th. Analysts expect the company to announce earnings of ($1.10) per share for the quarter.
Celsion Corporation (NASDAQ:CLSN) last announced its quarterly earnings results on Thursday, May 18th. The biotechnology company reported ($1.64) earnings per share for the quarter, missing the consensus estimate of ($1.30) by $0.34. The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion Corporation had a negative return on equity of 201.04% and a negative net margin of 4,299.60%. On average, analysts expect Celsion Corporation to post $-2.79 EPS for the current fiscal year and $-1.44 EPS for the next fiscal year.
Shares of Celsion Corporation (NASDAQ CLSN) opened at 1.31 on Wednesday. The firm’s 50-day moving average price is $2.01 and its 200 day moving average price is $0.95. The firm’s market capitalization is $5.33 million. Celsion Corporation has a 12 month low of $0.19 and a 12 month high of $4.96.
TRADEMARK VIOLATION WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/09/celsion-corporation-nasdaqclsn-set-to-announce-quarterly-earnings-on-thursday.html.
A number of research firms have commented on CLSN. Maxim Group restated a “hold” rating on shares of Celsion Corporation in a research note on Monday. Zacks Investment Research lowered shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research note on Monday, June 26th. Finally, ValuEngine upgraded shares of Celsion Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, May 31st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $25.38.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.